Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy

The efficacy of oncolytic adenoviruses is limited by strong immune responses being induced against the oncolytic virus itself. Here, the authors generate a bispecific molecule capable of redirecting the adenovirus-specific antibodies to tumour cells and show this induces immune mediated cancer growt...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julia Niemann, Norman Woller, Jennifer Brooks, Bettina Fleischmann-Mundt, Nikolas T. Martin, Arnold Kloos, Sarah Knocke, Amanda M. Ernst, Michael P. Manns, Stefan Kubicka, Thomas C. Wirth, Rita Gerardy-Schahn, Florian Kühnel
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/5216df34738f45e49e9168b8b9041417
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5216df34738f45e49e9168b8b9041417
record_format	dspace
spelling	oai:doaj.org-article:5216df34738f45e49e9168b8b90414172021-12-02T14:35:30ZMolecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy10.1038/s41467-019-11137-52041-1723https://doaj.org/article/5216df34738f45e49e9168b8b90414172019-07-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-11137-5https://doaj.org/toc/2041-1723The efficacy of oncolytic adenoviruses is limited by strong immune responses being induced against the oncolytic virus itself. Here, the authors generate a bispecific molecule capable of redirecting the adenovirus-specific antibodies to tumour cells and show this induces immune mediated cancer growth inhibition and enhances the therapeutic efficacy of viral oncolysis.Julia NiemannNorman WollerJennifer BrooksBettina Fleischmann-MundtNikolas T. MartinArnold KloosSarah KnockeAmanda M. ErnstMichael P. MannsStefan KubickaThomas C. WirthRita Gerardy-SchahnFlorian KühnelNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Julia Niemann Norman Woller Jennifer Brooks Bettina Fleischmann-Mundt Nikolas T. Martin Arnold Kloos Sarah Knocke Amanda M. Ernst Michael P. Manns Stefan Kubicka Thomas C. Wirth Rita Gerardy-Schahn Florian Kühnel Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
description	The efficacy of oncolytic adenoviruses is limited by strong immune responses being induced against the oncolytic virus itself. Here, the authors generate a bispecific molecule capable of redirecting the adenovirus-specific antibodies to tumour cells and show this induces immune mediated cancer growth inhibition and enhances the therapeutic efficacy of viral oncolysis.
format	article
author	Julia Niemann Norman Woller Jennifer Brooks Bettina Fleischmann-Mundt Nikolas T. Martin Arnold Kloos Sarah Knocke Amanda M. Ernst Michael P. Manns Stefan Kubicka Thomas C. Wirth Rita Gerardy-Schahn Florian Kühnel
author_facet	Julia Niemann Norman Woller Jennifer Brooks Bettina Fleischmann-Mundt Nikolas T. Martin Arnold Kloos Sarah Knocke Amanda M. Ernst Michael P. Manns Stefan Kubicka Thomas C. Wirth Rita Gerardy-Schahn Florian Kühnel
author_sort	Julia Niemann
title	Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
title_short	Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
title_full	Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
title_fullStr	Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
title_full_unstemmed	Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
title_sort	molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/5216df34738f45e49e9168b8b9041417
work_keys_str_mv	AT julianiemann molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT normanwoller molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT jenniferbrooks molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT bettinafleischmannmundt molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT nikolastmartin molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT arnoldkloos molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT sarahknocke molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT amandamernst molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT michaelpmanns molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT stefankubicka molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT thomascwirth molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT ritagerardyschahn molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy AT floriankuhnel molecularretargetingofantibodiesconvertsimmunedefenseagainstoncolyticvirusesintocancerimmunotherapy
_version_	1718391127383474176

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy

Ejemplares similares